title: Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
abstract: BACKGROUND
  Little is known about the use of biomarkers in guiding treatment decisions in routine asthma management. The objective of this study was to determine whether adding a LABA to an ICS would control bronchial hyperresponsiveness (BHR) at an overall lower dose of ICS when titration of medication was based upon the assessment of routine clinical measures with or without the measurement of BHR.
  
  
  METHODS
  After a 2-week run-in period, subjects (> or = 12 years) were randomized to one of three treatment groups. Two groups followed a BHR treatment strategy (based on clinical parameters [lung function, asthma symptoms, and bronchodilator use] and BHR) and were treated with either fluticasone propionate/salmeterol (FSC(BHR) group) or fluticasone propionate (FP(BHR) group) (n=156 each). The third group followed a clinical treatment algorithm (based on clinical parameters alone) and were treated with fluticasone propionate (FP(REF) group; n=154). All treatments were administered via Diskus. Treatment doses were adjusted as needed every 8 weeks for 40 weeks according to the subject's derived severity class, which was based on clinical measures of asthma control with or without BHR.
  
  
  RESULTS
  The mean total daily inhaled corticosteroids (ICS) dose during the double-blind treatment period was lower, although not statistically significant, in the FSC(BHR) group compared with the FP(BHR) group (a difference of -42.9 mcg; p=0.07). Compared with the FP(REF) group, the mean total daily ICS dose was higher in the FSC(BHR) group (a difference of 85.2 mcg) and was significantly higher in the FP(BHR) group (a difference of 131.2 mcg, p=0.037).
  
  
  CONCLUSIONS
  This study demonstrated that for most subjects, control of BHR was maintained when treatment was directed toward control of clinical parameters. In addition, there was a trend towards control of BHR and clinical measures at a lower dose of ICS when used concurrently with salmeterol.
authors.affiliation: Division of Pulmonary Medicine and Critical Care, University of Virginia, Hospital Drive, Private Clinics #6590, Charlottesville, VA 22908, USA. smk4q@virginia.edu
authors.forename: Steven M
authors.initials: SM
authors.lastname: Koenig
authors.forename: John J
authors.initials: JJ
authors.lastname: Murray
authors.forename: James
authors.initials: J
authors.lastname: Wolfe
authors.forename: Leslie
authors.initials: L
authors.lastname: Andersen
authors.forename: Steve
authors.initials: S
authors.lastname: Yancey
authors.forename: Barbara
authors.initials: B
authors.lastname: Prillaman
authors.forename: John
authors.initials: J
authors.lastname: Stauffer
authors.forename: Paul
authors.initials: P
authors.lastname: Dorinsky
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D019540:Area Under Curve; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D016535:Bronchial Hyperreactivity / Q000175:diagnosis / Q000188:drug therapy*; D016085:Bronchoconstrictor Agents; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007843:Latin America; D007844:Latvia; D008297:Male; D036501:Metered Dose Inhalers; D016210:Methacholine Chloride; D008875:Middle Aged; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome; D014481:United States
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D016085:Bronchoconstrictor Agents; D001993:Bronchodilator Agents; D016210:Methacholine Chloride; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol